Showing results (101-110 of 463) with videos related to

Sort By:
Pageof 47
Trends in Neurosciences|May 5, 2019
Dopaminergic Vulnerability in Parkinson Disease: The Cost of Humans' Habitual PerformanceLedia F Hernandez, Ignacio Obeso, Rui M Costa, et al.
Parkinsonism & Related Disorders|December 22, 2020
Can adenosine A2A receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson's disease?Peter Jenner, Akihisa Mori, Tomoyuki Kanda
The European Journal of Neuroscience|May 5, 2005
Increased osteopontin expression following intranigral lipopolysaccharide injection in the ratJoanna Iczkiewicz, Sarah Rose, Peter Jenner
Brain Research. Molecular Brain Research|November 19, 2004
Osteopontin (Eta-1) is present in the rat basal gangliaJoanna Iczkiewicz, Sarah Rose, Peter Jenner
Experimental Neurology|July 24, 2007
Osteopontin expression in activated glial cells following mechanical- or toxin-induced nigral dopaminergic cell lossJoanna Iczkiewicz, Sarah Rose, Peter Jenner
International Review of Neurobiology|September 23, 2023
How and why the adenosine A2A receptor became a target for Parkinson's disease therapyPeter Jenner, Tomoyuki Kanda, Akihisa Mori
Parkinsonism & Related Disorders|July 30, 2023
Importance of time to ON versus wearing OFF in total daily OFF time experienced by patients with Parkinson's diseaseStuart H Isaacson, Daniel Kremens, Yasar Torres-Yaghi, et al.
Journal of Neurology|July 29, 2003
Dual dopamine agonist treatment in Parkinson's diseaseFabrizio Stocchi, Laura Vacca, Alfredo Berardelli, et al.
Experimental Brain Research|March 26, 2013
Bilateral stimulation of the subthalamic nucleus has differential effects on reactive and proactive inhibition and conflict-induced slowing in Parkinson's diseaseIgnacio Obeso, Leonora Wilkinson, Maria-Cruz Rodríguez-Oroz, et al.
Pageof 47